Epertinib , CAS No.908305-13-5

CAS: 908305-13-5 Cat. No.: E646582 Summenformel: C30H27ClFN5O3 Molekulargewicht: 560.02 PubChem CID: 46701811
Zu bestellen verfügbar
Storage
Store at 2-8°C,Protected from light
Shipped In
Wet ice
★
Größe
Deutschland (EU)
USA*
Preis
Menge
1mg
E646582-1mg
Auf Bestellung · 8–12 Wochen
382,59€
Enter a quantity for the sizes you want to add.
🧪
Warum diese Qualität

für empfindliche chromatographische und analytische Workflows, die minimale Basislinieninterferenzen erfordern.

🌡

Lagerung & Versand

Store at 2-8°C,Protected from light Versand Wet ice. Genaue Spezifikationen finden Sie im chargenspezifischen COA.

📋

Qualitätsdokumente

SDS, COA, Datenblatt und Spezifikationsblatt stehen zum Download bereit. Chargenspezifische COA über Chargennummernsuche abrufbar.

📚

Literaturbeleg

In 0 peer-reviewten Publikationen zu Chromatographie, organischer Synthese und Kreuzkupplungsreaktionen zitiert.

Übersicht

Epertinib (S-22611) is a potent, orally active, reversible, and selective tyrosine kinase inhibitor of EGFR , HER4 and HER2 , with IC 50 s of 1.48 nM, 2.49 nM and 7.15 nM, respectively. Epertinib shows potent antitumor activity

In Vitro

Epertinib inhibits the phosphorylation of EGFR and HER2 in NCI-N87 cells, with IC 50 values of 4.5 and 1.6 nM, respectively. Epertinib shows inhibitory activity against MDA-MB-361 cell, with an IC 50 of 26.5 nM. Epertinib (0-10 μM, 72 h) can selectively inhibit the proliferation of a range of cancer cell lines expressing EGFR and/or HER2. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Proliferation AssayCell Line: NCI-N87 (stomach), BT-474 (breast), SK-BR-3 (breast), MDA-MB-453 (breast), MDA-MB-175VII (breast), HT115 (colon), Calu-3 (lung), fR2 (breast), and MRC-5 (lung) Concentration: 0-10 μM Incubation Time: 72 h Result: Inhibited the growth of NCI-N87, BT-474, SK-BR-3, MDA-MB-453, MDA-MB-175VII, HT115, Calu-3, fR2, and MRC-5, with IC 50 values of 8.3 ± 2.6, 9.9 ± 0.8, 14.0 ± 3.6, 48.6 ± 3.1, 21.6 ± 4.3, 53.3 ± 8.6, 241.5 ± 29.2, 5366.7 ± 65.2, and 4964.6 ± 340.3.

In Vivo

Epertinib (0-100 mg/kg, Orally, once daily for 28 days) shows antitumor activity . Epertinib (50 mg/kg, Orally, once daily for 30 days) significantly reduces the brain tumor volume . Epertinib (0-50 mg/kg, Orally, once daily for 10-28 days) significantly inhibits the tumor growth in a dose-dependent manner. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Nude mice (BALB/cAJcl-nu/nu, implanted intracranially with MDA-MB-361 or BR2 cells) Dosage: 12.5, 25, 50, 100  mg/kg Administration: Orally, once daily for 28 days Result: Showed antitumor activity in the mammary fat pad implantation model using both cell lines and the ED 50 values were comparable (24.1 mg/kg and 26.5 mg/kg for MDA-MB-361 and BR2 (MDA-MB-361-luc-BR2), respectively). Animal Model: Nude mice (BALB/cAJcl-nu/nu, implanted intracranially with MDA-MB-361 or BR2 cells) Dosage: 50 mg/kg Administration: Orally, once daily for 30 days Result: Significantly reduced the brain tumor volume, indicating that epertinib could have potent antitumor activity in brain metastasis even in the presence of an intact BTB (blood-tumor barrier). Animal Model: Nude mice (BALB/cAJcl-nu/nu, prepared by subcutaneous implantation of human gastric cancer cells, NCI-N87 into the back of nude mice)Dosage: 0, 6.25, 12.5, 25, and 50 mg/kg Administration: Oral gavage, daily for 10-28 days Result: Significantly inhibited the tumor growth in a dose-dependent manner.

Form:Solid

IC50& Target:EGFR 1.48 ± 0.0 nM (IC 50 ) HER4 2.49 ± 0.1 nM (IC 50 ) HER2 7.15 ± 0.5 nM (IC 50 )

Spezifikationen

Biochemische und physiologische Mechanismen
Epertinib (S-22611) is a potent, orally active, reversible, and selective tyrosine kinase inhibitor of EGFR , HER4 and HER2 , with IC 50 s of 1.48 nM, 2.49 nM and 7.15 nM, respectively. Epertinib shows potent antitumor activity.
Storage
Store at 2-8°C,Protected from light
Verschickt in
Wet ice
Dieses Produkt erfordert Kühlkettenversand. Grundversand und andere Economy-Optionen sind nicht verfügbar.
Aktionsart
INHIBITOR
Namen und Kennungen
Isomere SMILES
CC#C/C(=N\OC[C@H]1COCCN1)/C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl
PubChem CID
46701811
Molekulargewicht
560.02

Dokumentation

📋 Sicherheitsdatenblatt (SDS)

Umfassendes Dokument zu Gefahren, Handhabung, Lagerung und Einhaltung regulatorischer Vorschriften.

<<<<<<< HEAD SDS herunterladen → ======= SDS herunterladen → >>>>>>> release248-p3

✅ Analysezertifikat (COA)

Chargenspezifische Qualitätsdaten. Geben Sie Ihre Chargennummer ein, um das genaue COA abzurufen.

COA nachschlagen →

📊 Datenblatt

Kurzübersicht über Produktspezifikationen und Anwendungen.

Datenblatt ansehen →

🔬 Spezifikationsblatt

Vollständige Qualitätsmerkmale und Akzeptanzkriterien für diese Qualität.

Spezifikationsblatt ansehen →

Erweiterte Daten

Zertifikate (CoA, COO, BSE/TSE und Analyse-Diagramm)
C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:
Chemische und physikalische Eigenschaften
Molekulargewicht560.000 g/mol
XLogP36.100
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count9
Rotatable Bond Count10
Exact Mass559.179 Da
Monoisotopic Mass559.179 Da
Topological Polar Surface Area89.900 Ų
Heavy Atom Count40
Formal Charge0
Complexity899.000
Isotope Atom Count0
Defined Atom Stereocenter Count1
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count1
Undefined Bond Stereocenter Count0
The total count of all stereochemical bonds1
Covalently-Bonded Unit Count1
Lösungsrechner
Bewertungen

Kundenbewertungen

Dürfen wir Sie über Rabattaktionen informieren?

Später erinnern

Vielen Dank! Bitte überprüfen Sie Ihren E-Mail-Posteingang, um zu bestätigen.

Hoppla! Benachrichtigungen sind deaktiviert.